HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach
- 1 August 2000
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 13 (8), 866-873
- https://doi.org/10.1038/modpathol.3880154
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- The HercepTest Assay: Another PerspectiveJournal of Clinical Oncology, 1999
- Increased HER2 With U.S. Food and Drug Administration-Approved AntibodyJournal of Clinical Oncology, 1999
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Critical determination of the frequency of c-erbB-2 amplification in breast cancerBritish Journal of Cancer, 1994
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerThe New England Journal of Medicine, 1994
- Analysis of cerbB2 expression using a panel of 6 commercially available antibodiesPathology, 1994
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.Journal of Clinical Oncology, 1992
- Assessment of Antigen Damage in Immunohistochemistry: The Vimentin Internal ControlAmerican Journal of Clinical Pathology, 1991
- c‐erbB‐2 and c‐erbA‐1 (ear‐1) Gene Amplification and c‐erbB‐2 Protein Expression in Japanese Breast Cancers: Their Relationship to the Histology and Other Disease ParametersJapanese Journal of Cancer Research, 1990